New camera could make cancer treatment safer by better tracking radiation
NCT ID NCT04467567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new type of camera (VERITON-CT) can accurately measure radiation doses in patients receiving Lutathera, a treatment for certain cancers. Fifteen adults were scanned with both the new camera and a standard camera at different times after treatment. The goal was to see if the new camera could provide reliable dose information with fewer scans, which could make the process easier for patients and doctors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (lutetium Lu 177 dotatate)
What this could lead to
If successful, this could lead to a simpler, faster way to measure radiation doses during Lutathera treatment, potentially improving patient safety and treatment planning.
What could go wrong
This is a very small, early-stage study (15 people) focused on measurement methods, not treatment outcomes. The new camera may not prove more accurate or practical in routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chru Nancy
Vandœuvre-lès-Nancy, 54511, France